Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716961 | 0.98 | ALDH1A1 (0.40) | SLC7A5ALDH1A1NAAAPOLBCNR2 | |
| SCHEMBL6723179 | 0.98 | ALDH1A1 (0.40) | SLC7A5ALDH1A1NAAAPOLBCNR2 | |
| SCHEMBL6003373 | 0.95 | POLB (0.42) | SLC7A5ALDH1A1NAAAPOLBCNR2 | |
| SCHEMBL1432767 | 0.88 | AOC3 (0.39) | POLBSMN1; SMN2LMNAHTR2AKCNH2 | |
| SCHEMBL9572592 | 0.82 | CETP (0.42) | ALDH1A1CNR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17042680 | 0.82 | ALDH1A1 (0.40) | SLC7A5ALDH1A1NAAANPC1RAB9A | |
| SCHEMBL17042557 | 0.82 | ALDH1A1 (0.40) | SLC7A5ALDH1A1NAAANPC1RAB9A | |
| SCHEMBL2194257 | 0.81 | SLC7A5 (0.42) | SLC7A5ALDH1A1NAAAPOLBCNR2 | |
| SCHEMBL27372 | 0.80 | LMNA (0.42) | SLC7A5ALDH1A1POLBSMN1; SMN2LMNA | |
| SCHEMBL1459570 | 0.80 | SLC7A5 (0.44) | SLC7A5ALDH1A1NAAAPOLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | claimed |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | CAI GUOLIN (US) | 2002-03-21 | — | — | US | claimed |
| WO-2002000623-A2 | ARYL FUSED SUBSTITUTED 4-OXY-PYRIDINES | NEUROGEN CORPORATION (US) | 2002-01-03 | — | — | WO | claimed |
| EP-0446670-B1 | Method of preparation of amikacin precursors | OPOS BIOCHIMICA SRL (IT) | 1994-09-21 | — | — | EP | claimed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7371752-B2 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828329-B2 | Agonists, antagonists for gamma-aminobutyric acid brain receptors useful in diagnosis and treatment of anxiety depressionm, down syndrome, sleep and seizure disorders | NEUROGEN CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1158589-A1 | SECONDARY LITHIUM BATTERY, NEGATIVE ELECTRODE FOR SECONDARY LITHIUM BATTERY, AND PROCESS FOR PRODUCING THE NEGATIVE ELECTRODE | FUJITSU LIMITED (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-20010031396-A1 | Lithium secondary battery, anode for lithium secondary battery, and method for manufacturing the anode | FUJITSU LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-5998065-A | N-OXYIMIDE ADDITIVE | FUJITSU LIMITED (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| EP-0313081-A2 | 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| US-4464369-A | CEPHALOSPORINS, ANTIMICROBIALS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| EP-0088385-A2 | 7-Acylamino-3-cephem-4-carboxylic acid derivatives, processes for the preparation of the same and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | SLC7A5 121/4885ALDH1A1 3946/4885NAAA 1333/4885 |
| US-20050154008-A1 | Aryl fused substituted 4-oxy-pyridines | CHRNA7, CHRNA4, GABRA6 | SLC7A5 1293/4885ALDH1A1 1669/4885NAAA 3907/4885 |
| US-20020035121-A1 | Aryl fused substituted 4-oxy-pyridines | GABRA4, GABRA6, GABRG2 | SLC7A5 1463/4885ALDH1A1 1434/4885NAAA 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.